NO990436D0 - FremgangsmÕte for behandling av bipolar forstyrrelse - Google Patents

FremgangsmÕte for behandling av bipolar forstyrrelse

Info

Publication number
NO990436D0
NO990436D0 NO990436A NO990436A NO990436D0 NO 990436 D0 NO990436 D0 NO 990436D0 NO 990436 A NO990436 A NO 990436A NO 990436 A NO990436 A NO 990436A NO 990436 D0 NO990436 D0 NO 990436D0
Authority
NO
Norway
Prior art keywords
bipolar disorder
procedure
treatment
humans
chem
Prior art date
Application number
NO990436A
Other languages
English (en)
Other versions
NO990436L (no
Inventor
Franklin Porter Bymaster
Harlan Edgar Shannon
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO990436D0 publication Critical patent/NO990436D0/no
Publication of NO990436L publication Critical patent/NO990436L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Processing Of Solid Wastes (AREA)
  • Press Drives And Press Lines (AREA)
  • Steroid Compounds (AREA)
  • Nonmetallic Welding Materials (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Electrolytic Production Of Non-Metals, Compounds, Apparatuses Therefor (AREA)
NO990436A 1996-08-01 1999-01-29 FremgangsmÕte for behandling av bipolar forstyrrelse NO990436L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2290096P 1996-08-01 1996-08-01
PCT/US1997/013185 WO1998005324A1 (en) 1996-08-01 1997-07-28 Method for treating bipolar disorder

Publications (2)

Publication Number Publication Date
NO990436D0 true NO990436D0 (no) 1999-01-29
NO990436L NO990436L (no) 1999-01-29

Family

ID=21812011

Family Applications (1)

Application Number Title Priority Date Filing Date
NO990436A NO990436L (no) 1996-08-01 1999-01-29 FremgangsmÕte for behandling av bipolar forstyrrelse

Country Status (19)

Country Link
EP (1) EP0821955B1 (no)
JP (1) JP2000515547A (no)
KR (1) KR20000029647A (no)
CN (1) CN1226165A (no)
AT (1) ATE213413T1 (no)
AU (1) AU716972B2 (no)
BR (1) BR9710901A (no)
CA (1) CA2261802C (no)
CZ (1) CZ27299A3 (no)
DE (1) DE69710526T2 (no)
DK (1) DK0821955T3 (no)
EA (1) EA199900174A1 (no)
ES (1) ES2171838T3 (no)
HU (1) HUP9904578A2 (no)
IL (1) IL128280A0 (no)
NO (1) NO990436L (no)
PL (1) PL331407A1 (no)
PT (1) PT821955E (no)
WO (1) WO1998005324A1 (no)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10265311B2 (en) 2009-07-22 2019-04-23 PureTech Health LLC Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
WO2011011060A1 (en) 2009-07-22 2011-01-27 Puretech Ventures Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
CA3180743A1 (en) 2018-09-28 2020-04-02 Karuna Therapeutics, Inc. Composition comprising xanomeline and trospium for treating disorders ameliorated by muscarinic receptor activation
CN111430027B (zh) * 2020-03-18 2023-04-28 浙江大学 基于肠道微生物的双相情感障碍生物标志物及其筛选应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5043345A (en) * 1989-02-22 1991-08-27 Novo Nordisk A/S Piperidine compounds and their preparation and use
US5376668A (en) * 1990-08-21 1994-12-27 Novo Nordisk A/S Heterocyclic compounds
CZ285030B6 (cs) * 1993-08-19 1999-05-12 Novo Nordisk A/S Použití thiadiazolových a oxadiazolových sloučenin pro výrobu farmaceutického prostředku a farmacetický prostředek pro léčení schizofrenie nebo schizofrenních nemocí
US5672709A (en) * 1994-10-24 1997-09-30 Eli Lilly And Company Heterocyclic compounds and their preparation and use
US5488056A (en) * 1994-10-31 1996-01-30 Eli Lilly And Company Method for treating anxiety
DK0709094T3 (da) * 1994-10-31 2000-07-10 Lilly Co Eli Tetrahydropyridinoxadiazol- eller thiadiazolforbindelse til behandling af angst

Also Published As

Publication number Publication date
CZ27299A3 (cs) 1999-08-11
PT821955E (pt) 2002-07-31
BR9710901A (pt) 1999-08-17
JP2000515547A (ja) 2000-11-21
DE69710526T2 (de) 2002-10-02
CA2261802C (en) 2006-11-07
DE69710526D1 (de) 2002-03-28
HUP9904578A2 (hu) 2000-06-28
PL331407A1 (en) 1999-07-19
WO1998005324A1 (en) 1998-02-12
ATE213413T1 (de) 2002-03-15
EP0821955B1 (en) 2002-02-20
CA2261802A1 (en) 1998-02-12
EA199900174A1 (ru) 1999-08-26
DK0821955T3 (da) 2002-03-18
KR20000029647A (ko) 2000-05-25
AU716972B2 (en) 2000-03-09
EP0821955A2 (en) 1998-02-04
ES2171838T3 (es) 2002-09-16
AU4046897A (en) 1998-02-25
EP0821955A3 (en) 1998-04-22
CN1226165A (zh) 1999-08-18
NO990436L (no) 1999-01-29
IL128280A0 (en) 1999-11-30

Similar Documents

Publication Publication Date Title
ATE152111T1 (de) K-252a derivate
MX9302932A (es) Nuevas 4-aza-5&-androstan-3-onas 7b-substituidas como inhibidores de la5&-reductasa.
ATE271385T1 (de) Verwendung von cyclooxygenase-2 inhibitoren zur behandlung und verbeugung von neoplasia
DK0665013T3 (da) Behandling af hyperproliferative karsygdomme
DE69716810D1 (de) 2,3-Disubstituierte-(5,6)-heteroarylkondensierte-pyrimidin-4-one
PT768086E (pt) Tratamento de tinido utilizando agentes neuroprotectores
DE69331171T2 (de) Chinolin und Chinazolin Derivate zur Behandlung von Arthritis
MX9401175A (es) Inhibidores de la acetilcolinesterasa sililada.
ATE156359T1 (de) Phosphatdiester zur behandlung von proliferativen erkrankungen der epidermis
NO990436D0 (no) FremgangsmÕte for behandling av bipolar forstyrrelse
DK0655243T3 (da) Melatoninderivater til anvendelse ved behandling af søvnlidelser
DE69432626D1 (de) Melatonin-Derivate zur Verwendung in der Behandlung von Desynchronisierungs-Erkankungen
HUT70757A (en) Pharmaceutical compositions for treating skin disorders
NO984189D0 (no) Fremgangsmåte for behandling av bipolar forstyrrelse
ATE283269T1 (de) 5-(heteroaryl)alkyl)-3-oxo-pyrido(1,2- a)benzimidazol-4-carboxamid (pbi) derivate zur behandlung von störungen des zentralen nervensystems
DE69706195T2 (de) Antikonvulsive derivate zur behandlung von psoriasis
DK0810223T3 (da) Adamantylsubstituerede oxindoler som farmaceutiske midler